PureTech Health plc (PRTC.L)
LSE · GBp · Healthcare · Biotechnology
£114.40 (+0.35%) as of
Key statistics
- Market cap
- 280.50M
- Forward P/E
- -4.72
- EPS (TTM)
- 0.00
- Dividend yield
- 0.00%
- 52-week range
- 106.60 – 143.60
- Beta
- 0.81
- Revenue (TTM)
- 6.37M
- Profit margin
- 33.21%
- Analyst target
- £298.27
- Volume
- 68.97k
About PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 90
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.